Chester County News and Community Website
WEST CHESTER, PA — Verrica Pharmaceuticals Inc. (Nasdaq: VRCA) announced this week that Part 2 of its Phase 2 clinical trial for VP-315, a potential first-in-class oncolytic peptide, has yielded …
Verrica Pharmaceuticals Reports Promising Phase 2 Results for VP-315 in Basal Cell Carcinoma Read More
BERWYN, PA — Panavance Therapeutics Inc. has announced the publication of encouraging data on misetionamide in the peer-reviewed journal, Cancer Medicine. The study conducted by Kim et al. at MD …
Panavance Therapeutics Reports Positive Data on Misetionamide in Ovarian Cancer Read More
NEWTOWN SQUARE, PA — ArriVent BioPharma, Inc. (Nasdaq: AVBP) has announced that it will present significant interim findings from its randomized Phase 1b FURTHER study on firmonertinib monotherapy. This presentation …
ArriVent BioPharma to Present Groundbreaking Data at 2024 World Conference on Lung Cancer Read More
HARRISBURG, PA — Secretary of the Commonwealth Al Schmidt announced a dramatic increase in participation for the Cancer Drug Repository Program (CDRP), with the number of pharmacies involved jumping from …
Participation in Pennsylvania’s Cancer Drug Program Soars by 900% Read More
WASHINGTON, D.C. — The Food and Drug Administration (FDA) has announced that the national supply of cisplatin, a key cancer medication, now exceeds demand, ending a critical shortage that began …
FDA Announces End to National Shortage of Crucial Cancer Drug Cisplatin Read More
WASHINGTON, D.C. — The Food and Drug Administration (FDA) recently granted accelerated approval to Epkinly (epcoritamab-bysp), a new treatment option for adults with relapsed or refractory follicular lymphoma (FL). This …
FDA Grants Accelerated Approval to New Treatment for Relapsed Follicular Lymphoma Read More
PLYMOUTH MEETING, PA — The National Comprehensive Cancer Network® (NCCN®) has released new survey results highlighting persistent drug shortages in cancer treatment across the United States. While the availability of …
NCCN Survey Reveals Ongoing Cancer Drug Shortages Despite Improvements Read More
WASHINGTON, D.C. — The Food and Drug Administration (FDA) recently granted accelerated approval for a new treatment combination for adults with KRAS G12C-mutated locally advanced or metastatic colorectal cancer (CRC). …
FDA Grants Accelerated Approval to New Colorectal Cancer Treatment Read More
WASHINGTON, D.C. — On Monday, the Food and Drug Administration (FDA) approved pembrolizumab (Keytruda, Merck) in combination with carboplatin and paclitaxel, followed by single-agent pembrolizumab, for adult patients with primary …
FDA Approves Keytruda Combination for Advanced Endometrial Cancer Read More
WASHINGTON, D.C. — On Friday, the Food and Drug Administration (FDA) approved durvalumab (Imfinzi, AstraZeneca UK Limited) for use with carboplatin plus paclitaxel followed by single-agent durvalumab. This approval targets …
FDA Approves New Treatment for Advanced Endometrial Cancer Read More